Activity from announced rounds
Gaorong Ventures, also identified as Gaorong Capital, is the investment organization connected to Axoft and Moonwalk financing histories.
Moonwalk develops medicines targeting fat-tissue pathways, while Axoft develops implanted brain-computer interfaces. The recorded activity also includes Anew’s combination of molecular models and experimental biology for drug discovery. These companies pursue different clinical technologies.
Moonwalk Biosciences is developing adipose-targeted siRNA medicines for obesity and cardiometabolic disease. Its lead programs are designed to alter fat-tissue pathways while limiting effects on other tissues, with the lead obesity candidate in IND-enabling development ahead of planned human testing in 2027.
Develops implantable Brain-Computer Interfaces (iBCIs) for neurological disorders